number of patients studied is limited and all transplant recipients received a dose-reduced conditioning. Thus, in order to more broadly establish the role of MRD detection using chimerism analysis in marrow CD34 þ progenitors, confirmative studies in AML and potentially other leukemias, and particularly in transplant recipients treated with conventional conditioning regimens, will be required. Furthermore, the cutoff of 75% DCC was arbitrarily set and marrow CD34
Improved patient care and new immunosuppressive therapy regimens result in better post-transplant survival and contribute to a growing number of transplantations. Hence, the frequency of post-transplant malignancies increases. 1 Here, we describe a clinical case with unusual extramedullary presentation of an allograft-derived acute myeloid leukemia (AML) occurring 3 years after orthotopic liver transplantation (oLTX). HLA-typing, STR, cytogenetic and FICTION analyses proved this leukemia to be donor-derived. 2 To our knowledge, this is the first report demonstrating allograft-localized donor-derived leukemia.
The patient, a 43-year-old male, presented with mild fever, jaundice and abdominal pain. He had received an oLTX 3 years ago for nutritive-toxic liver cirrhosis (child C). The clinical course after oLTX was uncomplicated, including a routine check-up 1 month prior to admission. Laboratory findings on admission: leukocytes 9.0/ml (3.1-9.6/nl), Hb 8.2 g/dl (14-18 g/dl), platelets 280/nl (130-340/nl), hyperbilirubinemia 7.3 mg/dl, conjugated bilirubin 5.6 mg/dl (up to 1.0 mg/dl), alkaline phosphatase 470 U/l (60-180 U/l), g-glutamyl-transferase 67 U/l (up to 28 U/l), creatinine 1.7 mg/dl (up to 1.2 mg/ml), urea nitrogen 52 mg/dl (14-46 mg/dl) and uric acid 7.2 mg/dl (3.0-6.9 mg/dl). Other laboratory findings were normal. An abdominal ultrasound revealed a heterogeneous parenchymal structure in the liver, with a mass (2 cm) at the liver hilus, suspicious for a hepatic-biliary tract tumor. Two CT-guided biopsies revealed mild cellular rejection, grade I, without malignant cells. For complete diagnostics, a microscopic blood examination was performed. Surprisingly, this demonstrated 16% blasts, 60% neutrophils and 24% lymphocytes. Bone marrow (BM) aspiration showed infiltration of monoblasts expressing CD34, CD13 and CD33. Diagnosis of acute myelomonocytic leukemia (FAB M4) was made and extramedullary manifestation (liver/peritoneum) was assumed, but not proven as etiology of the cholestatic icterus. Reduced intensity chemotherapy (150 mg cytosine arabinoside/24 h infusion/ 6 days and 50 mg daunorubicin/1 day) was given as increased toxicity was expected. Abdominal symptoms and hyperbilirubinemia improved. The number of BM blasts was reduced to 20%.
Before reinduction chemotherapy, the patient exhibited an acute ileus with peritoneal thickening and a leukocytosis (23 000/ul) with 70% blasts. A peritoneal biopsy showed diffuse leukemic infiltration. A second course of chemotherapy (150 mg cytosine arabinoside/24 h/6 days and 40 mg daunorubicin, 1 day) was administered. Immunosuppressive therapy with tacrolimus was stopped. The clinical status worsened despite supportive therapy and the patient died at home 3 weeks later.
We provide evidence for donor origin of the leukemia. First, molecular HLA typing confirmed the presence of donor leukemia cells in the bone marrow (BM). Serological and molecular analyses of the recipient prior to oLTX revealed the HLA type: A2, A32, B41, B27, Bw4, Bw6, DRB1 n 01, DRB1 n 13 The allele length in base pairs at nine loci showed different STR pattern in recipient and donor DNA. and DRB3. The liver transplant showed the HLA-type: A2, A24, B27, B38, Bw4, Cw2, DR4, DR13, DR53, 52, DQ1, 3. Typing of BM leukemic cells revealed predominantly the donor HLA phenotype, whereas qualitative HLA-class II PCR analysis yielded the presence of donor and recipient HLA genotype: A2, A24, B27, B38, Bw4, Cw2, -, DRB1 n 01, DRB1 n 04, DRB1 n 13, DRB3, DRB4, DQB1 n 03, DQB1 n 05, DQB1 n 06. Second, short tandem repeat (STR) analyses were used for patient's buccal, liver biopsy and positively selected CD34 þ cells, which demonstrated two different patterns: one originating from the recipient and one from the donor (Table 1) . Buccal and CD34 þ cell analysis revealed major STR profile differences, whereas liver biopsy and CD34 þ cell profiles were almost identical, excluding leukemogenesis from another source, that is, transfusion 3 ( Figure 1 ). This strongly suggests donor-derived leukemia. Multiple chromosome analyses revealed a complex aberrant karyotype, including loss of chromosome 18 and a ring chromosome 5. Interestingly, minor differences in STR profiles between leukemia and liver cells matched to these observed cytogenetic alterations. The D13S317, FGA and D21S11 loci were chosen for donor/recipient calculations in sorted cells. The lymphoid
and mature myeloid (CD14 þ /15 þ ) cells originated from the recipient, whereas the CD34 þ PBMCs originated from the donor.
Third, leukemic cells, harboring the trisomy 13, as detected by fluorescence in situ hybridisation (FISH), were negative for the recipient specific HLA-Bw6 marker and positive for the donor-specific HLA-A24 marker (Figure 2) . The HLA expression of the tumor cells was determined using combined immunophenotyping and interphase cytogenetics (FICTION) on blood and BM cytospins. 4 HLA-A23/24-positive as well as Bw6-negative cells displayed a signal pattern indicating trisomy 13 in 84 and 36%. In contrast, the percentage of HLA-A23/24-negative as well as Bw6-positive with such a signal constellation was below the cutoff of FICTION (Table 2) . Taken together, these data clearly demonstrate that the leukemic cells originated from the transplant.
Interestingly, the clinical presentation was dominated by the extramedullary manifestation in the allograft itself. The immunohistological staining of the peritoneal biopsy demonstrated a strong, homogenous expression of CD34 þ on the infiltrating cell population, proving the extramedullary manifestation of the myeloid leukemia. Extramedullary hematological malignancies presenting initially with obstructive jaundice are rare. A single report describes an isolated granulocytic sarcoma of the porta hepatis causing obstructive jaundice in an 84-year-old man, as revealed by autopsy. 5 Furthermore, there are few allograft-located PTLD cases described. In three cases, donor derivation was proven. 6 Here, we show for the first time predominantly transplant-localized myeloid leukemia of donor origin after transplantation, as confirmed independently by three different techniques.
It remains unresolved, however, when the leukemic transformation took place, in particular, since there are no appropriate criteria for deciphering the time point of malignant transformation. One possibility is that the transformation occurred already in the donor. However, there was no evidence of leukemia at the time of donor death and, furthermore, both cadaveric kidney transplant recipients did not develop leukemia. Therefore, we favor the hypothesis that leukemic transformation of hematopoietic progenitor cells (HPC) occurred in the recipient. This would be in agreement with the reported transfer of HPC in LTX. 7 If the transformation took place in the recipient, one possibility would be that the immunosuppressive treatment or the immunosuppressive drug itself could have provided leukemogenic potential. Indeed, a recent report described an increased frequency of AML following transplantation. 8 However, this was significant only in the patient cohort taking azathioprine, a thioprine prodrug, as part of the immunosuppressive therapy. Our patient did not take azathioprine and a direct leukemogenic effect of tacrolimus or steroids, taken by our patient, has not been reported so far.
In any case, immunosuppressive therapy might have promoted leukemic outgrowth due to the impaired immune response of the recipient. The impact of the HLA-A, B and Bw donor/recipient haploidentity on leukemic outgrowth, which might have facilitated immune escape of leukemic cells, remains speculative. Taken together, we here clearly demonstrate donor origin of an acute myeloid leukemia with atypical clinical presentation in the transplanted organ after liver transplantation. Dual color fluorescence analysis for the detection of trisomy 13 and the donor specific HLA-A23/24 antigen on bone marrow cells. FISH-analysis using a DNA probe for the retinoblastoma gene on chromosome 13 (green) and immunphenotyping for the donor specific HLA class I antigen A23/24 (red) was used for dual color staining. DAPI was used for staining of the cell nucleus (blue). In 480% of the HLA-A23/24 positive staining cells a trisomy 13 was detected by FISH. In HLA-A23/24 negative cells a normal, double signal for the retinoblastoma gene (chromosome 13) was routinely detected. The trisomy 13 positive cells are therefore HLA-A23/24 positive and HLA-Bw6 negative, which is concordant with the HLA type of the liver donor. Dual color fluorescence analysis of BM cells for the detection of the leukemic specific trisomy 13 and the recipient (HLA-Bw6) and donor HLA (HLA-A23/24) class I antigen was used. In 480% of the HLA-A23/24-positive staining cells a trisomy 13 was detected by FISH, whereas in HLA-A23/24-negative cells a normal, double signal for the retinoblastoma gene (chromosome 13) was detected.
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